List of articles with "Obesity Treatment"

Viking VK2735 Trial Completed

Viking VK2735 Trial Completed

United States San Diego Viking Therapeutics Obesity Treatment VK2735
Palatin Q1 2026 Update

Palatin Q1 2026 Update

USA Palatin Technologies Princeton Obesity Treatment MC4R Agonists
CureGene's CG-0416

CureGene's CG-0416

China Shanghai CureGene Obesity Treatment CG-0416
Nitinotes EndoZip Approval

Nitinotes EndoZip Approval

Israel Caesarea Obesity Treatment EndoZip Nitinotes
MetaVia Q3 2025 Update

MetaVia Q3 2025 Update

United States Cambridge Obesity Treatment MetaVia Inc DA-1726
Promise of Eloralintide

Promise of Eloralintide

USA Indianapolis Eli Lilly Obesity Treatment eloralintide
VK2735 Trial Launch

VK2735 Trial Launch

USA San Diego Viking Therapeutics Obesity Treatment VK2735
Innovative Mechanism for Obesity

Innovative Mechanism for Obesity

USA Endevica Bio Northbrook, Illinois Obesity Treatment 710GO
Rona's Novel siRNA for Obesity

Rona's Novel siRNA for Obesity

USA Santa Barbara Obesity Treatment Rona Therapeutics RN3161
Lilly's Obesity Breakthrough

Lilly's Obesity Breakthrough

United States Indianapolis Eli Lilly Obesity Treatment Orforglipron
VK2735 Weight Loss Success

VK2735 Weight Loss Success

United States San Diego Viking Therapeutics Obesity Treatment VK2735
Radella's MD-18 Weight Loss

Radella's MD-18 Weight Loss

United States New York Obesity Treatment Radella Pharmaceuticals MD-18
Non-Surgical Obesity Treatment

Non-Surgical Obesity Treatment

Japan Tokyo Obesity Treatment Gastric Botox Kodai Takahashi
Ascletis ASC30 Study

Ascletis ASC30 Study

United States Hong Kong Ascletis Obesity Treatment ASC30
Viking Q2 2025 Update

Viking Q2 2025 Update

USA San Diego Viking Therapeutics Obesity Treatment VK2735
MC4R Agonist Advances

MC4R Agonist Advances

United States Boston Obesity Treatment MC4R agonist Superluminal
Healthcare Forum

Healthcare Forum

Japan Tokyo Healthcare Innovation Eli Lilly Obesity Treatment
MetaVia Phase 1 Trial

MetaVia Phase 1 Trial

United States Cambridge MetaVia Obesity Treatment DA-1726
RESET® Device CE Mark Success

RESET® Device CE Mark Success

USA Boston Obesity Treatment Morphic Medical RESET®
Low GLP-1 Drug Persistence

Low GLP-1 Drug Persistence

USA GLP-1 Eagan Obesity Treatment Prime Therapeutics
FDA Approval for EndoZip™

FDA Approval for EndoZip™

USA Caesarea Obesity Treatment Nitinotes EndoZip™
Obesity Treatment Update

Obesity Treatment Update

United States Obesity Treatment Belmont Supercede Therapeutics SPCD-4-79
GLP-1 Medications Breakthrough

GLP-1 Medications Breakthrough

USA Chicago Obesity Treatment GLP-1 Medications Type 2 Diabetes
Promising Results of MariTide

Promising Results of MariTide

United States California MariTide Amgen Obesity Treatment
Novo Nordisk Amycretin

Novo Nordisk Amycretin

United States Novo Nordisk Plainsboro Obesity Treatment amycretin
ADA Scientific Sessions

ADA Scientific Sessions

Obesity Treatment American Diabetes Association diabetes research
Rise in GLP-1 Usage

Rise in GLP-1 Usage

United States New York FAIR Health Obesity Treatment GLP-1 drugs
EndoZip™ Clinical Results

EndoZip™ Clinical Results

Israel Caesarea Obesity Treatment EndoZip Nitinotes
Ousia Pharma Funding

Ousia Pharma Funding

USA Boston Obesity Treatment Ousia Pharma Omega Funds
Ousia's Seed Financing

Ousia's Seed Financing

USA Boston Obesity Treatment Ousia Pharma Omega Funds
MetaVia DA-1726 Results

MetaVia DA-1726 Results

USA Cambridge MetaVia Obesity Treatment DA-1726
DA-1726 Clinical Trial Insights

DA-1726 Clinical Trial Insights

USA Cambridge MetaVia Obesity Treatment DA-1726
Gender Divide in Obesity Drugs

Gender Divide in Obesity Drugs

USA San Francisco Obesity Treatment Olio Labs GLP-1 drugs
Ascletis ASC47 Phase Ib Results

Ascletis ASC47 Phase Ib Results

USA Hong Kong ASC47 Obesity Treatment Ascletis Pharma
Hoth's GDNF Breakthrough

Hoth's GDNF Breakthrough

USA New York Hoth Therapeutics Obesity Treatment GDNF
Ascletis Phase Ib Results

Ascletis Phase Ib Results

USA Hong Kong Obesity Treatment ASC30 Ascletis Pharma
Innovative Patent for Obesity

Innovative Patent for Obesity

United States Huntington Obesity Treatment Sen-Jam Pharmaceutical metabolic disorders
Halia's Upcoming Events

Halia's Upcoming Events

USA San Francisco Healthcare Conference Halia Therapeutics Obesity Treatment
VK2735 Phase 2 Trial

VK2735 Phase 2 Trial

United States San Diego Viking Therapeutics Obesity Treatment VK2735
Hoth and VA Team Up

Hoth and VA Team Up

USA New York Hoth Therapeutics VA Department Obesity Treatment

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.